 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Strategic Shift and Financing Round Highlight VANI's Year-End SummaryRelated Stocks: VANI...

Vivani Medical Inc (VANI) Reports Fourth Quarter and Full Year 2023 Financial Results

Vivani Medical, Inc. (Nasdaq: VANI) (Vivani or the Company), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight...

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Maxim Group analyst Naz Rahman maintained a Buy rating on Vivani Medical (VANI Research Report) yesterday. The company's shares closed yesterday...

Maxim Group Sticks to Its Buy Rating for Vivani Medical (VANI)

Vivani Medical, Inc. (Nasdaq: VANI) (Vivani or the Company), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced the appointment of...

Vivani Medical Appoints Daniel Bradbury to its Board of Directors

Vivani Medical, Altamira Therapeutics, Quoin Pharmaceuticals among healthcare movers...

Vivani Medical, Altamira Therapeutics, Quoin Pharmaceuticals among healthcare movers

Vivani Medical, Inc. (Nasdaq: VANI) ('Vivani' or the 'Company'), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today...

Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants

Vivani Medical (NASDAQ: VANI) stock price surged hard this week after the company published positive results of its ongoing weight loss drug trial. The shares surged from about $1 and reached a high...

Vivani Medical (VANI) stock price surged: is it a good buy?

Vivani Medical, Inc. (Nasdaq: VANI) (Vivani or the Company), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced positive preclinical...

Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic/Wegovy and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio

Vivani Medical, Inc. (NASDAQ:VANI  Get Free Report) Director Gregg Williams bought 13,067 shares of the businesss stock in a transaction on Tuesday, January 16th. The stock was bought...

Gregg Williams Buys 13,067 Shares of Vivani Medical, Inc. (NASDAQ:VANI) Stock

Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. It operates under the Biopharm Division and Neuromodulation Division segments. The company was founded by Adam Mendelsohn on May 22, 2003 and is headquartered in Alameda, CA.

Volume (M)	88,427.00
52-Wk High	$7.80
52-Wk Low	$0.84

VANI Vivani Medical Inc

About

Feed

News

Earnings

Fundamentals